Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma.

Behling KC, Tang A, Freydin B, Chervoneva I, Kadakia S, Schwartz GF, Rui H, Witkiewicz AK.

Breast Cancer Res Treat. 2011 Oct;129(3):717-24. doi: 10.1007/s10549-010-1254-8. Epub 2010 Nov 19.

2.

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L.

Br J Cancer. 2012 Mar 13;106(6):1160-5. doi: 10.1038/bjc.2012.41. Epub 2012 Feb 23.

3.

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

4.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
5.

Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.

Aguiar FN, Mendes HN, Bacchi CE, Carvalho FM.

Rev Bras Ginecol Obstet. 2013 Mar;35(3):97-102.

6.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

7.

Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.

Stackievicz R, Paran H, Bernheim J, Shapira M, Weisenberg N, Kaufman T, Klein E, Gutman M.

Isr Med Assoc J. 2010 May;12(5):290-5.

PMID:
20929083
8.
9.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
10.

The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.

Cancer. 2004 Jun 1;100(11):2317-27.

11.

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):183-9. doi: 10.1016/j.clon.2011.09.008. Epub 2011 Sep 29.

PMID:
21958729
12.

Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.

Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr, Yu Y.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3660-6.

13.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N.

J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.

14.

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Salvucci O, Bouchard A, Baccarelli A, DeschĂȘnes J, Sauter G, Simon R, Bianchi R, Basik M.

Breast Cancer Res Treat. 2006 Jun;97(3):275-83. Epub 2005 Dec 13.

PMID:
16344916
15.

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL.

Hum Pathol. 1992 Sep;23(9):974-9.

PMID:
1355464
16.

Is there a low-grade precursor pathway in breast cancer?

King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.

PMID:
21935747
17.

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, Pilotti S, van de Vijver MJ.

Br J Cancer. 2001 Feb;84(4):539-44.

18.

Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.

Al Mushawah F, Rastelli A, Pluard T, Margenthaler JA.

J Surg Res. 2012 Mar;173(1):10-5. doi: 10.1016/j.jss.2011.04.058. Epub 2011 May 23.

PMID:
21696764
19.

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.

Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9. doi: 10.1158/1055-9965.EPI-08-1101. Epub 2009 Apr 21.

20.
Items per page

Supplemental Content

Write to the Help Desk